Monday September 11, 2017 – Friday September 15, 2017
On Monday, markets rallied strongly as fears of Hurricane Irma subsided. Even though it was a powerful storm, the worst case scenarios didn’t materialize. The Dow Industrials gained 259 points and the S&P 500 closed at a record high. Gold fell 1.1% to $1,335 an ounce.
On Tuesday, the JOLTS job openings report for July rose 0.9% to 6.17 million, higher than expected as the labor market continues to tighten. Financial stocks rallied as interest rates increased with the 10 year Treasury yielding 2.17%. Markets rose modestly with the Dow Industrials, S&P 500 and Nasdaq composite all closing at a record high.
On Wednesday, the producer price index for August showed a tame .2% increase and the EIA petroleum status report for the week ending September 8th saw crude oil inventory increase 5.9 million barrels. The dollar continued rising as the Trump administration kept pressure on Congress to pass tax reform and 10 year Treasuries rose to yield 2.2%. The Dow Industrials, S&P 500, and Nasdaq composite all rose slightly to finish at record highs.
On Thursday, the consumer price index for August rose .4%, and jobless claims for the week ending September 9th fell 14,000 to 284,000. Markets closed mixed on fears that increased inflation will prompt the Federal Reserve to raise interest rates, however, the Dow Industrials closed at a record high.
On Friday retail sales for August were weaker than expected, declining .2%, and industrial production for August dropped .9%. Markets opened modestly higher. Now let’s take a look at some stocks.
Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) announced on Monday that CooperSurgical will acquire PARAGARD, a product within Teva’s global Women’s Health business, in a $1.1 billion cash transaction. PARAGARD had revenues of approximately $168 million for the twelve-month period ending June 30th. Teva briefly broke above $20 per share Tuesday morning.
Aldeyra Therapeutics Inc. (NASDAQ: ALDX) shares jumped 34% on Tuesday after the company announced positive results from a Phase 2a clinical trial of its ADX-102 treatment in patients with dry eye disease. The stock gained another 34% on Thursday. The company said it expects to begin a phase 2b trial in the first half of 2018.
Centene Corporation (NYSE: CNC) announced that it would acquire privately owned Fidelis Care and enter into the New York health insurance market, sending Centene shares up over 6%. Under the terms of the agreement, Centene will acquire Fidelis for $3.75 billion. The acquisition will help expand Centene’s government sponsored healthcare coverage in New York.
Nordstrom, Inc. (NYSE: JWN) jumped about 6% on Wednesday after a report said Nordstrom family members were close to partnering with Leonard Green to take the retailer private. Family members own 31.2% of the department store and plan to raise between $7 and $8 billion in debt to finance the deal.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) stock was up more than 18% on Thursday after the biotechnology company announced that it has licensed its ENHANZE® drug-delivery technology to Roche. Under the terms of the agreement Halozyme will receive an initial $30 million with the potential to earn additional payments of up to $160 million subject to achievement of specified milestones. Halozyme will also receive tiered royalties on sales of commercialized products.